We develop innovative drugs that stimulate pro-survival cell-signaling processes for the treatment of neuro-degenerative diseases. Our initial focus is on ALS - a disease with no cure that leads to rapid death with a large addressable market. Our drug overcomes signaling deficiencies induced by the disease conditions and has potential to succeed where many other drugs failed. After a successful Phase 2a we are now preparing for Phase 2b/3 in ALS.